Journal
BLOOD
Volume 142, Issue 10, Pages 861-862Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2023021050
Keywords
-
Categories
Ask authors/readers for more resources
This study examines the long-term outcomes of pembrolizumab, an immune checkpoint inhibitor, in patients with relapsed/refractory classic Hodgkin lymphoma (HL).
In this issue of Blood, Armand et al describe the long-term outcomes of a phase 2 study of the immune checkpoint inhibitor pembrolizumab in patients with relapsed/refractory classic Hodgkin lymphoma (HL).1
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available